Life Science News

Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced that it has entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation.

Danaher Beacons is a new initiative designed to access breakthrough science to create technologies and applications that will improve human health. The program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.

"Collaboration is key to advancing science. Visionary academic leaders are a primary source of innovative solutions for tomorrow's medicines, which is why Beacons is geared toward academic institutions," said Vanessa Almendro , Vice President and Head of Innovation, Science and Technology, Danaher Corporation.

Dr. Aravind Asokan , a synthetic virologist and Duke professor of surgery and biomedical engineering will lead the Danaher Beacon for Gene Therapy Innovation. The focus of this Beacon will be on product solutions that address bottlenecks impacting viral vector manufacturing yield and quality.

"We are pleased to engage with Danaher in a strategic collaboration to streamline the clinical translation and manufacturing of new genomic medicines," Asokan said. "Breakthrough innovations are needed for this field to fulfill its promise in meeting needs of patients and their families."

"Dr. Asokan's expertise, directed at the intersection of biology and manufacturing, is a great example of the innovative drive required to realize the promise of gene therapy. We are excited about the promise of our newly formed partnership," Almendro added.

The partnership began in late October 2022 and is expected to run for multiple years.

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential . For more information, please visit www.danaher.com .

FORWARD-LOOKING STATEMENTS

Statements in this release that are not strictly historical are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2021 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2022. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Cision View original content: https://www.prnewswire.com/news-releases/danaher-launches-beacon-initiative-and-its-first-partnership-focused-on-gene-therapy-innovation-301675012.html

SOURCE Danaher Corporation

News Provided by PR Newswire via QuoteMedia

DHR

INN Video: Ian Graham of Discovery Harbour Resources

Discovery Harbour Resources Corp. (TSXV:DHR) President and CEO, Ian Graham, spoke with Resource Investing News on its flagship project, Wabassi, located in northern Ontario. “We’ve put our arms around an entire Greenstone Belt hosted VMS Mineral District. This is, as far as I’m aware, Canada’s most recent discovery of a new mineral district,” states Mr. Graham. In 2013, investors can expect the mobilization of drilling on the project, with news expected to come out in July. “Based on that news, we will be financing the Company a little further in the fall,” Mr. Graham says.

Keep reading...Show less

Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider

  • Launching in December for Constipation Awareness Month, Initiatives Include Partnerships with Well-Known Lifestyle and Health Care Practitioner Influencers
  • Campaign Coincides with Salix's Continued Support of Advocacy Groups Building Innovative Patient Education Programs and Advancing Disease State Research in 2023

Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), today announced the launch of a series of social media and digital initiatives to raise awareness during Constipation Awareness Month in December. The initiatives will discuss constipation diseases, including opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It is estimated that approximately up to 80% of patients receiving opioid medications for chronic pain experience OIC,1 30 million adults have CIC,2,3 and 3.4 million have IBS-C.2,3

The initiatives launching this month culminate a year in which Salix invested in a multipronged educational campaign that included the publication of digital content reaching more than 240 million consumers with valuable information about the symptoms of OIC, IBS-C, and CIC and treatment options they can discuss with their health care providers.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board

Alex Gorsky to Step Down After 30-Year Career at Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief transitional period.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the Bausch Health debt documents

The Company continues to evaluate potential options to maximize stakeholder value, which include its ongoing focus on its balance sheet and liquidity.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Viemed Announces New Senior Secured Credit Facilities

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced that it has entered into new syndicated credit facilities, consisting of a five-year senior secured revolving credit facility of up to $30 million and a five-year delayed draw term loan facility of up to $30 million, which may be borrowed in multiple drawdowns. The new credit facilities contain an accordion feature that allow the Company to increase the size of the facilities by up to $30 million, subject to certain conditions, for a total borrowing capacity of up to $90 million. Concurrently with the entry into the new credit facilities, the Company retired its previous senior credit facility, which included a $10 million unfunded line of credit commitment and a building term note in the principal amount of $4.7 million, scheduled to expire and mature in 2023 and 2026, respectively.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic executives to speak at the Evercore ISI 5th annual HealthCONx conference

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Evercore ISI 5 th annual HealthCONx conference on Tuesday, November 29 2022.

Geoff Martha , Medtronic chairman and chief executive officer, and Karen Parkhill , executive vice president & chief financial officer, will answer questions on the company beginning at 5:10 p.m. EST ( 4:10 p.m. CST ).

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
2 Biggest Medical Device ETFs in 2022

2 Biggest Medical Device ETFs in 2022

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less

Latest Press Releases

Related News

×